Sean Bohen, Olema
November 19, 2020 08:14 AM EST
Financing

Sean Bo­hen hauls in a mul­ti­mil­lion-dol­lar wind­fall as his new­ly adopt­ed biotech bags a $209M-plus IPO

John Carroll

Editor & Founder

Sean Bo­hen’s IPO for Ole­ma On­col­o­gy priced at $19 a share overnight, go­ing over the top of the range and giv­ing him an ini­tial mul­ti­mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times